The Degenerative Disc Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Degenerative Disc Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Degenerative Disc Disease Market.

Some of the key takeaways from the Degenerative Disc Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Degenerative Disc Disease treatment therapies with a considerable amount of success over the years. 
• Degenerative Disc Disease companies working in the treatment market are AnGes, Inc., Biosplice Therapeutics, Angitia Biopharmaceuticals, DiscGenics, Kuros Biosciences, BioRestorative Therapies, Mesoblast, Ltd., Spine Biopharma, and others, are developing therapies for the Degenerative Disc Disease treatment 

• Emerging Degenerative Disc Disease therapies such as – AMG0103, SM04690, AGA111, IDCT, KUR 113, BRTX-100, Rexlemestrocel-L, SB 01, and others are expected to have a significant impact on the Degenerative Disc Disease market in the coming years.   
• In January 2023, VySpine, the LumiVy NanoVy Ti Lumbar IBF System, which is indicated for intervertebral body fusion for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis, has received 510(k) clearance from the FDA
• In January 2023, In order to develop and market a Notogen regenerative therapeutic that has the potential to become a first-in-class, disease-modifying treatment for people with degenerative disc disease (DDD), Notogen, Inc. announced that it had entered a worldwide research collaboration and licence agreement with Boehringer Ingelheim
• In August 2022, Spine BioPharma, Inc. initiated a trial titled, “A Phase 3, Multi-center, Randomized, Double blind, Placebo-controlled Study, to Evaluate the Safety and Efficacy of SB-01 For Injection for the Treatment of Lumbar Degenerative Disc Disease”
• In March 2022, Spine BioPharma, Inc., a biopharmaceutical company committed to developing non-opiate, non-surgical therapies for the treatment of pain and disability from chronic low back pain caused by degenerative disc disease, announced the completion of a $13 million Series B equity financing
• In April 2022, South Korean pharmaceutical firm Yuhan Corp. announced its degenerative disc drug licensed out to an American drug company will go on Phase 3 clinical trial in the United States. U.S.-based Spine BioPharma has been given permission from the U.S

Degenerative Disc Disease Overview

Degenerative disc disease (DDD) represents a wide category of back pain resulting from or associated with the degeneration of intervertebral discs. It involves a process where the intervertebral discs lose height and hydration. When this occurs, the discsare unable to fulfill their primary functions of cushioning and providing mobility between the vertebrae.

Get a Free Sample PDF Report to know more about Degenerative Disc Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight

Emerging Degenerative Disc Disease Drugs Under Different Phases of Clinical Development Include:

• AMG0103: AnGes, Inc.
• SB-01: Spine BioPharma, Inc.
• SM04690: Biosplice Therapeutics
• AGA111: Angitia Biopharmaceuticals
• IDCT: DiscGenics
• KUR 113: Kuros Biosciences
• BRTX-100: BioRestorative Therapies
• Rexlemestrocel-L: Mesoblast, Ltd.
• SB 01: Spine Biopharma

Route of Administration

Degenerative Disc Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Degenerative Disc Disease Pipeline Therapeutics Assessment

• Degenerative Disc Disease Assessment by Product Type
• Degenerative Disc Disease By Stage and Product Type
• Degenerative Disc Disease Assessment by Route of Administration
• Degenerative Disc Disease By Stage and Route of Administration
• Degenerative Disc Disease Assessment by Molecule Type
• Degenerative Disc Disease by Stage and Molecule Type

DelveInsight’s Degenerative Disc Disease Report covers around 15+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Degenerative Disc Disease product details are provided in the report. Download the Degenerative Disc Disease pipeline report to learn more about the emerging Degenerative Disc Disease therapies

Some of the key companies in the Degenerative Disc Disease Therapeutics Market include:

Key companies developing therapies for Degenerative Disc Disease are – Spine BioPharma, Inc., Angitia Biopharmaceuticals, Mesoblast, Ltd., BioRestorative Therapies, DiscGenics, Inc., Biosplice Therapeutics, Notogen, AnGes, Inc., FibroGenesis, Genequine Biotherapeutics, Causeway Therapeutics, Boehringer Ingelheim, SpineOvations, BIOPHARM GmbH, Yuhan, Histogen Inc., and others.

Degenerative Disc Disease Pipeline Analysis:

The Degenerative Disc Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Degenerative Disc Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Degenerative Disc Disease Treatment.
• Degenerative Disc Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Degenerative Disc Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Degenerative Disc Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Degenerative Disc Disease drugs and therapies

Degenerative Disc Disease Pipeline Market Drivers

• Increase in the prevalence of Degenerative Disc Disease, increasing Research and Development activities are some of the important factors that are fueling the Degenerative Disc Disease Market.

Degenerative Disc Disease Pipeline Market Barriers

• However, cost associated with the treatment, poor patient compliance and other factors are creating obstacles in the Degenerative Disc Disease Market growth.

Scope of Degenerative Disc Disease Pipeline Drug Insight    

• Coverage: Global
• Key Degenerative Disc Disease Companies: AnGes, Inc., Biosplice Therapeutics, Angitia Biopharmaceuticals, DiscGenics, Kuros Biosciences, BioRestorative Therapies, Mesoblast, Ltd., Spine Biopharma, and others
• Key Degenerative Disc Disease Therapies: AMG0103, SM04690, AGA111, IDCT, KUR 113, BRTX-100, Rexlemestrocel-L, SB 01, and others
• Degenerative Disc Disease Therapeutic Assessment: Degenerative Disc Disease current marketed and Degenerative Disc Disease emerging therapies
• Degenerative Disc Disease Market Dynamics: Degenerative Disc Disease market drivers and Degenerative Disc Disease market barriers 

Request for Sample PDF Report for Degenerative Disc Disease Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services